辅助治疗对高级别胶质瘤复发时间的影响  

Effects of adjunctive therapies of high-grade glioma on delaying recurrence time

作　　者：杨与敏[1] 刘之一[1] 龙晓东[1] 

机构地区：[1]德阳市人民医院神经外科,四川德阳618000

出　　处：《岭南现代临床外科》2015年第2期172-174,共3页Lingnan Modern Clinics in Surgery

摘　　要：目的分析高级别胶质瘤术后辅助治疗（伽玛刀、常规分割放射治疗、化疗以及同步放化疗）对其平均复发时间的影响。评估辅助治疗对高级别胶质瘤的临床疗效。方法收集德阳市人民医院神经外科2008年1月～2013年12月间收治的具有完整病历资料的高级别脑胶质瘤复发患者64例。分为28例单纯手术治疗患者（A组）;36例行辅助治疗患者（B组）包括：10例术后行伽玛刀治疗患者（Ⅰ组）;4例术后行常规分割放射治疗患者（Ⅱ组）;3例术后行化疗患者（Ⅲ组）;19例术后行同步放化疗患者（Ⅳ组）。分析不同组别平均复发时间。结果 A组平均复发时间为7.804个月;B组平均复发时间为13.431个月;Ⅰ组平均复查时间为11.450个月;Ⅱ组平均复发时间为8.000个月;Ⅲ组平均复发时间为13.167个月;Ⅳ组平均复发时间为15.659个月。A组与B组及Ⅳ组之间有统计学差异。A组与Ⅰ组、Ⅱ组及Ⅲ组间无统计学差异。结论同步放化疗对高级别胶质瘤的平均复发时间有一定延缓作用。Objective To investigate the effects of postoperative concomitant therapies of highgrade glioma（gamma knife, radiotherapy, chemotherapy, synchronization chemoradiation） on delaying median relapse time and assess the clinical significance of postoperative concomitant therapy. Methods Sixty-four patients with recurring high-grade glioma patients in Deyang People＇s Hospital between Jan2008 to Dec 2013 were included in the study. Of them, 28 patients were treated with only operation（A group）, 36 patients treated with postoperative concomitant therapy（B group）. In B group, 10 patients were treated with postoperative gamma knife（I group）, 4 patients received postoperative radiotherapy（Ⅱ group）, 3 patients received postoperative chemotherapy（Ⅲ group）, 19 patients were treated with postoperative synchronization chemoradiation（Ⅳ group）. Analyse the median relapse time among the groups. Results The median relapse time is 7.804 months in A group, 13.431 months in B group; 11.450 months in Ⅰ group, 8.000 months in Ⅱ group; 13.167 months in Ⅲgroup, 15.659 months in Ⅳ group. It has statistical significance between A group and B group, also between A group and Ⅳ group. But it has no statistical significance among A group and other groups.Conclusion Synchronization chemoradiation is effective for postponing median relapse time of Highgrade glioma.

关 键 词：胶质瘤 手术 放疗 化疗 伽玛刀 

分 类 号：R651.1[医药卫生—外科学] R739.41[医药卫生—临床医学]